Researchers investigated whether popular immunotherapy drugs used to treat melanoma might cause bone loss as a side effect. The study focused on nivolumab and pembrolizumab, powerful immune-boosting medications that help prevent melanoma from returning. Scientists used bone density scans and blood tests to measure bone health in patients receiving these treatments. While the trial was terminated early with only 12 participants enrolled, it highlights an important concern about long-term effects of cancer immunotherapy. Understanding these potential bone-related side effects could help doctors better protect patient health during and after cancer treatment.
